Nasdaq

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

NEW YORK and MELBOURNE, Australia, July 30, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing ...
Nasdaq

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’s Proprietary Drug for Treatment of Obstructive Sleep Apnoea ...

MELBOURNE, Australia, July 06, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique ...
Medical Dialogues

USFDA Issues Warning Letter to Clinical Investigator Linked to Alembic Bioequivalence Study

Alembic Pharmaceuticals Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) ...
RAPS

FDA Offers Specific Guidance on Bioequivalence Trials for Next Generation of 38 Generic Drugs

The US Food and Drug Administration (FDA) on Thursday unveiled 38 new specific recommendations on the types of bioequivalence trials generic drug companies should run in order to win approval for ...
CNBCTV18

Alembic Pharma shares fall after USFDA issues warning letter linked to Vadodara facility

Alembic Pharmaceuticals said the warning letter relates to a clinical investigator involved in a study carried out at Alembic ...